PARK MEDI WORLD LIMITED
₹220.25-₹1.05 (-0.5%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹6,504 Cr
- P/E
- 906.0x
- EV / EBITDA
- 214.8x
- Revenue
- ₹91.6 Cr
- Net margin
- 8.4%
- ROCE
- 11.1%
Price chart
Technical chartScreen technicals →+36.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -19.9%
- 3M
- -21.1%
- 6M
- -4.3%
- 1Y
- +36.0%
- 5Y
- +42.1%
52-week range
Day change -₹1.05 (-0.5%) from ₹221 to ₹220 · Last close Oct 30, 2026
AI Summary
Indian StockStrengths1
- Operating margin of 28.7% exceeds Healthcare median (24.8%)
Concerns1
- Low interest coverage ratio of 1.9x
Rule-based from financial data. Not advice.
About the company
Park Medi World Limited operates a network of hospitals. The company provides internal medicine, neurology, urology, gastroentereology, general surgery, orthopedics, and oncology treatment services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.
- Sector
- Healthcare
- Shares outstanding
- 43.1 Cr shares
- ISIN
- INE119201023
- BSE code
- 544645
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹6,504 Cr
- P/E
- 906.0x
- EV / EBITDA
- 214.8x
- EV / Sales
- 73.9x
- P/S
- 72.6x
- Earnings yield
- 0.1%
- 52-week high
- ₹299.65
- 52-week low
- ₹143.95
Profitability
- Operating margin
- 28.7%
- Net margin
- 8.4%
- EBITDA margin
- 34.4%
- ROE
- 7.0%
- ROCE
- 11.1%
- ROA
- 2.7%
- Dividend payout
- 0.0%
- Tax rate
- 40.1%
- Other income, % of PBT
- 41.2%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹91.6 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.3%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹30.8 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.1%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -4.3%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹48.1 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.9%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹8.02 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 0.9%
Solvency and efficiency
- Current ratio
- 4.23
- Debt / Equity
- 1.18
- Debt / Assets
- 0.45
- Debt / EBITDA
- 4.07
- Interest coverage
- 1.88
- Financial leverage
- 2.60
- CFO / Net profit
- 6.41
- Cash / Market cap
- 0.7%
- Cash per share
- ₹0.98
- Asset turnover
- 0.32
- Fixed asset turnover
- 1.23
- Capital intensity
- 0.81
- Debtor days
- 90 days
- Inventory turnover
- 183.42
- Cash conversion cycle
- -257 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹8 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹68 Cr |
| Sales | Operating profit | ₹24 Cr |
| Operating profit | Interest | ₹12 Cr |
| Operating profit | Depreciation | ₹5 Cr |
| Operating profit | Profit before tax | ₹7 Cr |
| Other income | Profit before tax | ₹2 Cr |
| Profit before tax | Tax and other | ₹2 Cr |
| Profit before tax | Net profit | ₹7 Cr |
Revenue and net profit
Revenue grew 2.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | ₹110 Cr | ₹8 Cr |
| FY2023 | ₹102 Cr | ₹7 Cr |
| FY2024 | ₹90 Cr | ₹8 Cr |
| FY2025 | ₹92 Cr | ₹7 Cr |
Cash flows
FY2025: ₹9.29 Cr from operations, -₹22.2 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -₹10 Cr | ₹9 Cr |
| FY2023 | ₹45 Cr | ₹6 Cr |
| FY2024 | ₹48 Cr | -₹3 Cr |
| FY2025 | ₹9 Cr | -₹22 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹92 Cr+2.3%1Y
- Net profit
- ₹7 Cr-4.3%1Y
- Cash from operations
- ₹9 Cr-80.7%1Y
- Free cash flow
- -₹22 Cr
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹92 Cr | ₹24 Cr | — | ₹7 Cr | ₹9 Cr | -₹22 Cr | 6.3% | +2.3% | -4.3% |
Monthly returns
Month-by-month returns of PARKHOSPS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹320 Cr |
| Equity capital | ₹77 Cr |
| Reserves | ₹37 Cr |
| Borrowings | ₹158 Cr |
| Other liabilities | ₹47 Cr |
| Assets | ₹320 Cr |
| Fixed assets | ₹75 Cr |
| Capital work in progress | ₹37 Cr |
| Investments | ₹149 Cr |
| Other assets | ₹59 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
PARKHOSPS trades at 906.0x earnings against a peer median of 52.6x (a 1622% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| PARK MEDI WORLD LIMITEDPARKHOSPSthis companyP/E ↑ premium | ₹6,504 Cr | 906.0x | — | 7.0% | 214.8x |
| Sudeep Pharma LimitedSUDEEPPHRM | ₹7,027 Cr | 73.5x | — | 29.3% | 49.9x |
| Akums Drugs and Pharmaceuticals LimitedAKUMS | ₹6,983 Cr | 50.9x | 2.9x | -114.6% | -133.2x |
| Aarti Pharmalabs LimitedAARTIPHARM | ₹6,923 Cr | 28.3x | 3.6x | 12.4% | 19.5x |
| FDC Ltd.FDC | ₹6,387 Cr | 27.0x | 2.6x | 14.6% | 14.2x |
| YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITEDYATHARTH | ₹6,186 Cr | 67.3x | 3.9x | 10.0% | 45.5x |
| Kovai Medical Center & Hospital LtdKOVAI | ₹6,071 Cr | 26.6x | 5.1x | 20.2% | 17.2x |
| Supriya Lifescience LimitedSUPRIYA | ₹5,938 Cr | 32.6x | 5.5x | 14.6% | 31.4x |
| Shilpa Medicare Ltd.SHILPAMED | ₹5,771 Cr | 52.6x | 2.2x | 1.3% | 53.7x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
PARKHOSPS since 1 January, against earlier years.
Historical volatility
PARKHOSPS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 18.8% |
| FY2023 | 23.3% |
| FY2024 | 28.7% |
| FY2025 | 26.3% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹92 Cr |
| Costs | |
| Interest | ₹12 Cr |
| Expenses | ₹68 Cr |
| Operating profitOperating Profit | ₹24 Cr |
| Other income and charges | |
| Profit before tax | ₹9 Cr |
| Tax | |
| Net profitNet Profit | ₹7 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹320 Cr |
| Equity capitalEquity Capital | ₹77 Cr |
| Reserves | ₹37 Cr |
| Borrowings | ₹158 Cr |
| Other liabilitiesOther Liabilities | ₹47 Cr |
| AssetsTotal Assets | ₹320 Cr |
| Fixed assetsFixed Assets | ₹75 Cr |
| Capital work in progressCWIP | ₹37 Cr |
| Investments | ₹149 Cr |
| Other assetsOther Assets | ₹59 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹9 Cr |
| Investing cash flowCash from Investing Activity | -₹31 Cr |
| Financing cash flowCash from Financing Activity | ₹24 Cr |
| Change in cashNet Cash Flow | ₹1 Cr |
Learn while you research
Academy chapters picked for PARK MEDI WORLD LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 906.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read